Cargando…

Ursodeoxycholic acid production by Gibberella zeae mutants

Ursodeoxycholic acid (UDCA) is a highly demanded pharmaceutical steroid widely used in medicine. An ascomycete Gibberella zeae VKM F-2600 is capable of producing UDCA by 7β-hydroxylation of lithocholic acid (LCA). The present study is aimed at the improvement of the fungus productivity. The original...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollerov, Vyacheslav, Donova, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360310/
https://www.ncbi.nlm.nih.gov/pubmed/35939125
http://dx.doi.org/10.1186/s13568-022-01446-2
_version_ 1784764300524519424
author Kollerov, Vyacheslav
Donova, Marina
author_facet Kollerov, Vyacheslav
Donova, Marina
author_sort Kollerov, Vyacheslav
collection PubMed
description Ursodeoxycholic acid (UDCA) is a highly demanded pharmaceutical steroid widely used in medicine. An ascomycete Gibberella zeae VKM F-2600 is capable of producing UDCA by 7β-hydroxylation of lithocholic acid (LCA). The present study is aimed at the improvement of the fungus productivity. The original procedures for the protoplast obtaining followed by UV mutagenesis and screening of ketoconazole-resistant mutant clones have been applied. The highest yield of G. zeae protoplasts was obtained when using the mycelium in the active growth phase, ammonium chloride as an osmotic stabilizer and treatment of the fungal cells by the lytic enzymes cocktail from Trichoderma hurzanium. The conditions for effective protoplast regeneration and the UV-mutagenesis were found to provide 6–12% survival rate of the protoplasts with superior number of possible mutations. Three of 27 ketoconazole-resistant mutant clones obtained have been selected due to their increased biocatalytic activity towards LCA. The mutant G. zeae M23 produced 26% more UDCA even at relatively high LCA concentration (4 g/L) as compared with parent fungal strain, and the conversion reached 88% (w/w). The yield of UDCA reached in this study prefers those ever reported. The results contribute to the knowledge on ascomycete mutagenesis, and are of importance for biotechnological production of value added cholic acids. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9360310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93603102022-08-10 Ursodeoxycholic acid production by Gibberella zeae mutants Kollerov, Vyacheslav Donova, Marina AMB Express Original Article Ursodeoxycholic acid (UDCA) is a highly demanded pharmaceutical steroid widely used in medicine. An ascomycete Gibberella zeae VKM F-2600 is capable of producing UDCA by 7β-hydroxylation of lithocholic acid (LCA). The present study is aimed at the improvement of the fungus productivity. The original procedures for the protoplast obtaining followed by UV mutagenesis and screening of ketoconazole-resistant mutant clones have been applied. The highest yield of G. zeae protoplasts was obtained when using the mycelium in the active growth phase, ammonium chloride as an osmotic stabilizer and treatment of the fungal cells by the lytic enzymes cocktail from Trichoderma hurzanium. The conditions for effective protoplast regeneration and the UV-mutagenesis were found to provide 6–12% survival rate of the protoplasts with superior number of possible mutations. Three of 27 ketoconazole-resistant mutant clones obtained have been selected due to their increased biocatalytic activity towards LCA. The mutant G. zeae M23 produced 26% more UDCA even at relatively high LCA concentration (4 g/L) as compared with parent fungal strain, and the conversion reached 88% (w/w). The yield of UDCA reached in this study prefers those ever reported. The results contribute to the knowledge on ascomycete mutagenesis, and are of importance for biotechnological production of value added cholic acids. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2022-08-08 /pmc/articles/PMC9360310/ /pubmed/35939125 http://dx.doi.org/10.1186/s13568-022-01446-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kollerov, Vyacheslav
Donova, Marina
Ursodeoxycholic acid production by Gibberella zeae mutants
title Ursodeoxycholic acid production by Gibberella zeae mutants
title_full Ursodeoxycholic acid production by Gibberella zeae mutants
title_fullStr Ursodeoxycholic acid production by Gibberella zeae mutants
title_full_unstemmed Ursodeoxycholic acid production by Gibberella zeae mutants
title_short Ursodeoxycholic acid production by Gibberella zeae mutants
title_sort ursodeoxycholic acid production by gibberella zeae mutants
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360310/
https://www.ncbi.nlm.nih.gov/pubmed/35939125
http://dx.doi.org/10.1186/s13568-022-01446-2
work_keys_str_mv AT kollerovvyacheslav ursodeoxycholicacidproductionbygibberellazeaemutants
AT donovamarina ursodeoxycholicacidproductionbygibberellazeaemutants